Mitokany: protirakovinné látky cílené k mitochondriím jakožto zlepšení terapie a související patentové dokumenty

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F06%3A00096869" target="_blank" >RIV/68378050:_____/06:00096869 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Mitocans: Mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents

Popis výsledku v původním jazyce

Mitochondria are proving to be worthy targets for activating specific killing of cancer cells. The mechanism of action of mitochondrial targeted anti-cancer drugs relies on their ability to disrupt the energy producing systems of cancer cell mitochondria, leading to increased ROS and activation of the mitochondrial dependent cell death signaling pathways inside cancer cells. We propose that this emerging class of drugs be called "mitocans", a term that reflects their mitochondrial targeting and anti-cancer roles. They are discussed in this review in the context of their mode of action whereby they target the functional differences and altered properties of the mitochondria inside cancerous but not normal cells. A recent surge has occurred, in particular, in the number of patent documents describing small molecule inhibitors and BH3 mimetic blockers of Bcl-2/Bcl-x(L) function. It is early to judge the clinical impact of mitocans, but it is clear that they offer great potential.

Název v anglickém jazyce

Mitocans: Mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents

Popis výsledku anglicky

Mitochondria are proving to be worthy targets for activating specific killing of cancer cells. The mechanism of action of mitochondrial targeted anti-cancer drugs relies on their ability to disrupt the energy producing systems of cancer cell mitochondria, leading to increased ROS and activation of the mitochondrial dependent cell death signaling pathways inside cancer cells. We propose that this emerging class of drugs be called "mitocans", a term that reflects their mitochondrial targeting and anti-cancer roles. They are discussed in this review in the context of their mode of action whereby they target the functional differences and altered properties of the mitochondria inside cancerous but not normal cells. A recent surge has occurred, in particular, in the number of patent documents describing small molecule inhibitors and BH3 mimetic blockers of Bcl-2/Bcl-x(L) function. It is early to judge the clinical impact of mitocans, but it is clear that they offer great potential.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2006

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Recent Patents on Anti-Cancer Drug Discovery

ISSN

1574-8928

e-ISSN

—

Svazek periodika

1

Číslo periodika v rámci svazku

-

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

20

Strana od-do

327-346

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—